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Background. Early virological failure of antiretroviral therapy associated with the selection of drug-resistant
human immunodeficienc virus type 1 in treatment-naive patients is very critical, because virological failure
significantl increases the risk of subsequent failures. Therefore, we evaluated the possible role of minority qua-
sispecies of drug-resistant human immunodeficienc virus type 1, which are undetectable at baseline by population
sequencing, with regard to early virological failure.
Methods. We studied 4 patients who experienced early virological failure of a first-lin regimen of lamivudine,
tenofovir, and either efavirenz or nevirapine and 18 control patients undergoing similar treatment without viro-
logical failure. The key mutations K65R, K103N, Y181C, M184V, and M184I in the reverse transcriptase were
quantifie by allele-specifi real-time polymerase chain reaction performed on plasma samples before and during
early virological treatment failure.
Results. Before treatment, none of the viruses showed any evidence of drug resistance in the standard genotype
analysis. Minority quasispecies with either the M184V mutation or the M184I mutation were detected in 3 of 18
control patients. In contrast, all 4 patients whose treatment was failing had harbored drug-resistant viruses at low
frequencies before treatment, with a frequency range of 0.07%–2.0%. A range of 1–4 mutations was detected in
viruses from each patient. Most of the minority quasispecies were rapidly selected and represented the major virus
population within weeks after the patients started antiretroviral therapy. All 4 patients showed good adherence to
treatment. Nonnucleoside reverse-transcriptase inhibitor plasma concentrations were in normal ranges for all 4
patients at 2 separate assessment times.
Conclusions. Minority quasispecies of drug-resistant viruses, detected at baseline, can rapidly outgrow and
become the major virus population and subsequently lead to early therapy failure in treatment-naive patients who
receive antiretroviral therapy regimens with a low genetic resistance barrier.
The use of combination antiretroviral therapy (ART)
has remarkably reduced the morbidity and mortality of
subjects infected with HIV [1], but these benefit can
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be compromised by the development of drug resistance
[2]. Since the firs reports of primary infection with
drug-resistant HIV-1, transmission of drug-resistant
HIV strains has been a growing concern [3–5].
Because primary infection with a resistant strain may
decrease the efficac of initial therapy, resistance testing
before initiation of ART, in the context of recent and
even established HIV-1 infection, is recommended [6].
However, one major limitation of techniques such as
population sequencing is the inability to detect drug-
resistant minority quasispecies unless they represent
20%–25% of the total population [7]. Allele-specifi
real-time PCR (AS-PCR) allows the detection of mi-
nority quasispecies with discriminatory abilities to de-
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tect viral variants that represent as little as 0.01% of the pop-
ulation. Using this technique, we have shown that drug-resis-
tant HIV variants could be detected in 20% of acute serocon-
verters; the drug-resistant virus population was detected by
population sequencing in only one-half of those patients [8].
The clinical importance of minority quasispecies has yet to be
determined. To date, only a few observations have shown that
minority quasispecies of drug-resistant viruses can emerge as
major virus populations after initiation of salvage therapy in
pretreated patients [9–11].
Virological failure of ART significantl increases the risk of
clinical progression and, when associated with the appearance
of drug-resistant viruses, limits further treatment options [12,
13]. Therefore, early virological failure (eVF) within a fewweeks
after ART initiation in treatment-naive patients is especially
troublesome. Several reasons have been identifie for eVF as-
sociated with HIV-1 drug resistance, such as poor adherence
to treatment, drug combinations with low antiretroviral po-
tencies, or pharmacokinetics issues (e.g., malabsorption and
drug interactions) [14–17]. Here, we addressed the role of mi-
nority quasispecies of drug-resistant viruses involved in the eVF
of treatment-naive patients. Four patients experienced eVF de-
spite excellent adherence and adequate drug plasma levels dur-
ing treatment with a potent first-lin nonnucleoside reverse-
transcriptase inhibitor (NNRTI)–based regimen that was cho-
sen after baseline resistance testing. Therefore, we conducted a
case-control analysis of baseline and on-treatment samples by
AS-PCR assays for reverse-transcriptase (RT) mutations K65R,
K103N, Y181C, M184V, and M184I, and we compared the
results with those of standard virtual phenotype analysis using
population sequencing performed on the same samples.
METHODS
Study design and patients. All patients were treated at the
University Hospital of Lausanne from March 2005 through
August 2006. We identifie as case patients those who expe-
rienced eVF while receiving first-lin NNRTI-based regimen
despite good adherence to treatment (as certifie by directly
observed therapy or weekly community visits by a qualifie
nurse), adequate antiretroviral drug plasma levels, and no HIV-
1 drug resistance at baseline (determined by population se-
quencing). Control patients were selected retrospectively on the
basis of characteristics as follows: no failure associated with
first-lin NNRTI-based regimen within the firs 9 months of
treatment, no resistance mutations at baseline, and HIV-1 sub-
types and baseline viral loads comparable to those of the case
patients. To confi m that case and control patients had no
resistance mutations at baseline by population sequencing, 2
investigators performed a blind review of all fl orograms of
the sequences. The baseline characteristics of case and control
patients are summarized in tables 1 and 2, respectively. Plasma
sampling took place before and during ART. All patients agreed
to plasma sampling and resistance testing.
HIV quantificatio and resistance testing. Plasma HIV-1
RNA was quantifie using the Cobas AmpliPrep/Cobas TaqMan
HIV-1 Test (Roche Diagnostics), with a detection limit of 40
HIV-1 RNA copies/mL of plasma. Resistance testing by pop-
ulation sequencing was performed by using VirtualPhenotype
(Virco).
AS-PCR for the detection and quantificatio of minority
quasispecies of K65R, K103N, Y181C, M184V, and M184I
drug-resistant HIV-1 variants. Up to 2 blood samples ob-
tained before the start of ART, all follow-up samples obtained
until the start of second-line treatment for case patients, and
1 baseline sample from control patients were tested by AS-PCR
assays, which were performed blind. Evaluation of discrimi-
natory abilities and validation of the K103N and M184V AS-
PCR assays were described elsewhere [8, 18]. AS-PCRs of the
K65R, Y181C, and M184I mutations and their corresponding
wild-type variants are described in the Appendix.
Statistical analysis. To investigate the significanc of dif-
ferences in the presence of minority quasispecies at baseline in
both groups of patients, statistical analysis was performed using
the 2-tailed Fisher’s exact probability test for binary data. P
values !.05 were considered to be signif cant.
RESULTS
Case patients. Four treatment-naive patients received lami-
vudine, tenofovir, and nevirapine (3 patients) or efavirenz (1
patient) as their firs ART regimen. Treatment for patient 3 was
switched from nevirapine to efavirenz after 8 weeks because of
gastrointestinal adverse effects. Patient characteristics are sum-
marized in table 1. For case patients, viral load at baseline had
a range of 430,000–1,440,000 HIV-1 RNA copies/mL of plasma.
Before initiation of ART, resistance testing was performed by
population sequencing. No evidence of drug resistance was
observed in any of the 4 patients (figu e 1). All patients were
monitored with regard to plasma concentrations of the NNRTI.
Measurement of plasma NNRTI concentration after 2 weeks
of treatment and after 1–2 months showed values for efavirenz
in the upper range in patient 2 and at the ∼50th percentile for
nevirapine in patient 3. Nevirapine concentrations were within
normal ranges in patients 1 and 4. For all case patients, viral
load decrease at 4–7 weeks had a range of 0–1 log, and viral
load remained 1100,000 HIV-1 RNA copies/mL of plasma until
the start of second-line treatment. A second resistance test with
use of standard genotyping was performed 9–27 weeks after
starting the first-lin regimen (figu e 1). Viruses of all patients
harbored multiple mutations that conferred resistance to la-
mivudine, to NNRTIs, and, partly, to tenofovir. Salvage therapy
was initiated 15–31 weeks after the start of the fir t-line regi-
men. Second-line regimens included zidovudine (2 patients) or
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Figure 1. Kinetics of viral load and quantification of minority quasispecies of drug-resistant viruses in patients who received their first antiretroviral
therapy (ART) and experienced early virological failure within the first weeks. HIV-1 RNA in plasma was measured using the Cobas AmpliPrep/Cobas
TaqMan HIV-1 Test, with a lower limit of 40 copies/mL of plasma (black circles). Genotype data are depicted (gray arrows) and were obtained by
population sequencing with use of the VirtualPhenotype analysis; “none” means that no mutations associated with drug resistance were detected in
the reverse transcriptase [19]. Quantification of drug-resistant variants carrying the K65R, K103N, Y181C, M184V, or M184I mutation and drug-susceptible
viruses was performed by allele-specific PCR. The percentage of the virus population carrying the specific mutation was used to calculate the absolute
HIV-1 RNA copies/mL of plasma of the drug-resistant quasispecies on the basis of the corresponding total viral load measurement. Copy numbers
representing the K65R variant (green circles), K103N variant (pink circles), Y181C variant (red circles), M184V variant (blue circles), and M184I variant
(yellow circles) are shown. The thin black line indicates the limit of the viral load and allele-specific PCR measurements (40 HIV-1 RNA copies/mL of
plasma). Percentages (SD) of each drug-resistant virus population are given. 3TC, lamivudine; !DL, below detection limit; EFV, efavirenz; NA, not
applicable (because of negative results for both wild-type and mutant sequences); ND, not determined; NVP, nevirapine; TDF, tenofovir.
stavudine (2 patients) in combination with 2 boosted protease
inhibitors. After 6–14 weeks of salvage therapy, all patients
reached a viral load !400 HIV-1 RNA copies/mL of plasma.
Undetectable levels (!40 HIV-1 RNA copies/mL of plasma)
were achieved in all patients after 19–71 weeks of salvage ther-
apy (table 1).
Retrospectively, the key resistance mutations K65R, K103N,
Y181C, M184V, andM184I within the RT were further analyzed
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by sensitive AS-PCR, which allowed the quantificatio of mi-
nority quasispecies of drug-resistant viruses. In all 4 patients,
1–4 drug resistance mutations were detected at frequencies of
0.07%–2.0% before initiation of first-lin ART. The K103N
mutation was found in 1 patient; the Y181C and the M184V
or M184I variants were found in 3 patients (figu e 1). Rapid
selection of those variants and the additional appearance of 1
or 2 of those mutations, which were not detectable at baseline,
were observed in all patients.
In patient 1, the K103N, Y181C, M184V, and M184I mu-
tations were detected as minority quasispecies at low fre-
quencies, with a range (SD) of to0.07% 0.01% 2.0%
at baseline (figu e 1). Five weeks after starting ART,0.6%
of viruses already carried the Y181C mutation,99.3% 0.0%
which remained at those levels through week 21. The K103N
mutation was temporarily selected; ∼37.7% of viruses harbored
the K103N mutation at week 5, 18.5% of viruses harbored the
mutation at week 18, and this frequency further decreased at
week 21, to (figu e 1), which suggests that the1.39% 0.25%
Y181C mutation alone was sufficien to confer resistance
against nevirapine. The K65R mutation was not detected before
ART; however, of viruses already harbored the23.3% 1.3%
K65R mutation at week 5. This frequency increased to levels
199% at weeks 18 and 21. Both the M184V and the M184I
mutations were present in similar frequencies before ART was
initiated. The M184V mutation remained at low frequencies
(!1% at weeks 5 and 18), and the M184I mutation was selected
and was represented in of the virus population95.2% 0.6%
at week 18. The K65R, Y181C, and M184I mutations were also
detected by population sequencing at week 21 (f gure 1).
In patient 2, the M184V and the M184I mutations were
present at baseline as minor variants at similar frequencies. For
this patient, the M184V mutation was consequently selected
during therapy failure, and the M184I mutation remained a
minority quasispecies at frequencies of 1%–2%. The K65R,
K103N, and Y181C mutations were not detectable as minority
quasispecies before ART. In addition, none of those mutations
were developed and selected in this patient. Of those 3 mu-
tations, only the K103N mutation was detected, at very low
levels, at week 27 ( ). The presence of theM184V0.02% 0.00%
mutation as a major virus population was confi med by pop-
ulation sequencing. For this patient, other mutations (K70E,
G190E/Q, and K219D/E/N)—in addition to the M184V mu-
tation—led to eVF (fi ure 1).
In patient 3, the Y181C mutation already represented in
of viruses before ART, increased to1.1% 0.1% 54.7%
at week 4, and remained at this level during the following2.0%
7 weeks. The K103N mutation was detectable for the fi st time
at week 7, at a frequency of , and increased2.03% 0.04%
rapidly during the following 4 weeks, to , after98.42% 0.58%
the switch from nevirapine to efavirenz at week 8. The K65R
mutation was undetectable at baseline; however, 28.5%
of viruses harbored this mutation at week 4. No further4.0%
selection was observed; the K65R mutation remained at fre-
quencies of 20%–22% at weeks 7 and 11. A similar pattern was
observed with regard to the M184I mutation. This variant was
undetectable at baseline and represented of the45.9% 4.6%
virus population at week 7 and represented at35.1% 3.3%
week 11. The M184V mutation was never detectable in this
patient.
In patient 4, after initiation of ART, we also observed a rapid
selection of the Y181C mutation, which was already present at
baseline at a frequency of . In addition, the K103N1.1% 0.0%
mutation was selected and was represented in 14.81%
of viruses at week 9, although it had not been detected3.88%
at baseline. As was observed in patient 1, viruses containing
the M184I mutation (which was present for patient 4 at baseline
at a frequency of ) were selected as a major virus1.0% 0.1%
population despite the presence of the M184V mutation as a
minority quasispecies at weeks 2 and 6 ( and0.8% 0.2%
, respectively) (figu e 1). Thus, mutations that0.6% 0.1%
confer resistance against lamivudine and nevirapine were rap-
idly selected, but no mutation associated with resistance to
tenofovir was identifie in this patient.
Control patients. Control patients suppressed virus repli-
cation to undetectable levels within 5–41 weeks after treatment
initiation (table 2). Genotypic resistance testing by population
sequencing was performed for all control patients before ART
initiation. No mutations associated with drug resistance were
identified None of the mutations K65R, K103N, and Y181C
were present as minority quasispecies in the control group.
Control patients 10 and 17 harbored the M184I mutation (at
frequencies of and , respectively). In1.0% 0.1% 2.1% 0.4%
patient 9, of viruses harbored the M184V mu-14.1% 0.3%
tation before ART initiation (table 2); however, this did not
lead to eVF.
Therefore, only 3 of 18 patients who efficientl suppressed
virus replication after starting ART harbored minority quasi-
species of viruses that carried either the M184V or the M184I
mutation at baseline. In contrast, 1–4 drug resistance mutations
were present as minority quasispecies at baseline in all 4 patients
who experienced eVF. With use of the 2-tailed Fisher’s exact
probability test for the calculation of significance those dif-
ferences are significan on the basis of numbers of patient with
and without detectable minority quasispecies of drug-resistant
HIV-1 at baseline (3 of 18 patients vs. 4 of 4 patients; Pp
)..005
DISCUSSION
Although the number of treatment-naive patients who expe-
rienced eVF within just weeks after starting ART is, fortunately,
low [20], eVF is particularly problematic for the patient and
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the physician, especially when poor adherence can be excluded
as the reason for eVF. Further reasons for nonresponse to fi st-
line ART despite good adherence are currently not well un-
derstood. Here, we show that the presence of drug-resistant
viruses in low frequencies at baseline—that is, those not de-
tected by conventional genotypic testing—is associated with
eVF, because of rapid selection of those drug-resistant viruses
in 4 of 4 patients, despite well-documented, excellent adherence
and adequate drug plasma levels. We exclude nonadherence as
the reason for eVF among our patients for several reasons. Two
of 4 patients received directly observed therapy. One patient,
who lived in a refugee home, had weekly community surveil-
lance of drug intake by a nurse who used a weekly pill rack.
Drug concentrations in plasma were within normal ranges in
all 4 patients. In addition, all patients showed an optimal
(195%) adherence to the second-line regimen, which was sur-
veyed by medication event–monitoring systems.
Several studies have shown that minority quasispecies of
drug-resistant viruses can be found despite negative results of
standard genotyping. This was clearly demonstrated in women
after treatment with single-dose nevirapine to prevent mother-
to-child transmission of HIV-1 [21, 22], as well as in acute
seroconverters [8], patients undergoing structured treatment
interruptions [18], and patients experiencing virological failure
[10]. However, the clinical implications of minority quasispe-
cies of drug-resistant viruses are still unclear. Some observations
suggest that minority quasispecies of drug-resistant viruses can
emerge as major virus populations after initiation of salvage
therapy in pretreated patients [9–11, 23], but so far, only scarce
evidence exists that the minority quasispecies can affect the
outcome of first-lin therapy. One case report demonstrated
the emergence of minority quasispecies of drug-resistant viruses
in a previously treatment-naive patient who initiated ART;
however, several other drug resistance mutations were detected
by population sequencing at baseline in this patient, which
suggests that drug-resistant HIV-1 had been transmitted [24].
Our own data from the Primary HIV-1 Infection Cohort in
Zurich, Switzerland, and a study in France showed no signif-
icant difference between the outcome of first-lin therapy in
acutely or recently HIV-1 infected patients who carried mi-
nority quasispecies of drug-resistant viruses and those who did
not [25, 26]. In contrast to our current study, most of those
patients received 2 nucleoside reverse-transcriptase inhibitors
and a boosted protease inhibitor and, thus, ART regimens with
high genetic resistance barriers. Recently, Johnson et al. [27]
showed a correlation between the presence of minority qua-
sispecies of drug-resistant viruses at baseline and virological
failure in treatment-naive patients who received efavirenz-la-
mivudine and abacavir or zidovudine. Standard genotyping af-
ter treatment failure revealed the selection of those variants in
4 of 7 patients, which supports our results. However, no detailed
information is available with regard to adherence to treatment
by patients in that study. In a previous study [28], we observed
a rapid selection of drug-resistant HIV-1 variants in patients
who showed a slow decrease in viral load after starting their
firs ART, independent of preexisting minority quasispecies of
drug-resistant viruses. However, few patients were treated with
an NNRTI, and the regimen was intensifie within weeks for
all patients who experienced a slow decrease in viremia.
We show for the firs time, to our knowledge, that patients
can experience eVF despite good adherence; no evidence, by
population sequencing, of transmission of drug-resistant HIV-
1; and a potent ART regimen, as evidenced by the presence of
minority quasispecies of drug-resistant viruses before the start
of ART and subsequent rapid selection of those variants. Al-
though the number of patients was small and the study was
performed retrospectively, all patients were treated with a sim-
ilar regimen and during the same time period. One limitation
of our study is the small proportion of nevirapine-based reg-
imens used to treat control patients. The issue of a higher
efficac of efavirenz over nevirapine is still a matter of debate
[29]. However, the largest randomized, controlled trial that
compared efavirenz with nevirapine (2NN study [30]) did not
reveal a statistically significantl higher virological failure rate
in the nevirapine arm. In addition, the AS-PCR analyses were
performed blind. Therefore, our data strongly support the hy-
pothesis that minority quasispecies of drug-resistant viruses
have clinical implications in certain settings. In this context, it
has to be emphasized that all 4 patients were treated with a
first-lin regimen that was characterized by low genetic barrier
to resistance. Especially with regard to first-lin regimens con-
taining efavirenz or nevirapine, it might be possible to identify
patients at risk of failure by more-sensitive methods, such as
AS-PCR.
The pattern of drug-resistant minority quasispecies found in
our patients deserves another important consideration. The
impact of minority quasispecies of drug-resistant viruses at
baseline appears to be dependent on the specifi mutation de-
tected. Both the M184V and the M184I mutations were found
at baseline at similar frequencies in 3 patients who experienced
eVF. Interestingly, the M184V mutation was selected in 1 of
those patients, whereas theM184Imutation was rapidly selected
in 2 other patients and contributed to eVF. This is in contrast
with the observation that viruses harboring the M184V mu-
tation are more replication competent than are viruses har-
boring the M184I mutation [31]. Moreover, the M184V and
M184I mutations were also found in 3 control patients for
whom the presence of those mutations at baseline did not lead
to eVF. This shows that a mutation at codon 184 of the RT
alone is not necessarily associated with therapy failure and sug-
gests that the addition of other mutations in drug-resistant
minority quasispecies may be required to develop failure [32].
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In contrast, all 3 patients who harboredminority quasispecies
with the Y181C mutation rapidly selected this virus population,
which led to eVF. We found the K103N mutation at baseline
in 1 patient, but the frequency remained low, and only the
Y181C mutation was detected by conventional genotyping per-
formed 21 weeks after initiation of firs ART. The selection of
the Y181C mutation rather than K103N variants may be ex-
plained by the regimen, which contained nevirapine in these 3
patients. Nevirapine has been associated more frequently with
the selection of the Y181C mutation in patients who experience
failure of ART [2]. Taken together, these observations suggest
that drug-resistant quasispecies have different implications with
regard to the dynamics of virological failure. The Y181C mu-
tation appears to have a major role, whereas the presence of
the M184V mutation or the M184I mutation does not nec-
essarily lead to virological failure. This is consistent with clinical
observations and is probably related to the fitnes characteristic
of the mutations [33]. In addition, the number or composition
of different drug resistance mutations that are detectable as
minority quasispecies at baseline might be important.
Notwithstanding great advances in the treatment of HIV
infection and the availability of increasing possibilities for drug
combinations, virological success of the first-lin regimen re-
mains crucial for a good long-term prognosis [12, 13]. By using
AS-PCR, we were able to show a rapid outgrow of minority
quasispecies of drug-resistant viruses, undetected at baseline by
conventional genotyping, that led to eVF despite excellent ad-
herence and a potent standard regimen of lamivudine, teno-
fovir, and either efavirenz or nevirapine. Further studies to
confi m the clinical benefi of the detection of minority qua-
sispecies of drug-resistant viruses before starting ART in treat-
ment-naive patients are warranted, especially in the context of
ART regimens with low genetic barriers to resistance.
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APPENDIX
ALLELE-SPECIFIC REAL-TIME PCR (AS-PCR)
FOR THE DETECTION AND QUANTIFICATION
OF MINORITY QUASISPECIES OF K65R,
Y181C, AND M184I DRUG-RESISTANT HIV-1
VARIANTS
AS-PCRs of the K65R, Y181C, and M184I mutations and their
corresponding wild-type variants were designed and tested fol-
lowing the same procedures as described elsewhere [8, 18].
Plasma sampling, HIV-1 RNA isolation, and viral cDNA syn-
thesis and amplificatio were performed as described elsewhere
[8, 18]. In brief, 4 separate short-cycle firs PCRs were per-
formed to optimize the primer binding sites with use of the
following primers: (1) K103 EP1 [8], M184 EP1 [18], K103
EP2 [8], and M184 EP2 [18] in a multiplex PCR; (2) K65 EP1
5′-ACTCCAGTATTTGCCATAAAG-3′ (nucleotides [nt] 2721–
2741; nt positions are based on the reference strain HXB2) and
K103 EP2 [8]; (3) Y181 EP1 5′-TCAGTACAATGTGCTTC-
CAC-3′ (nt 2981–3000) and Y181 EP2 5′-CATACAAATCATC-
CATGTATTG-3′ (nt 3′093–3114); and (4) [M184I EP1 5′-TAT-
CAGTACAATGTGCTTCCAC-3′ (nt 2979–3000) and M184I
EP2 5′-GTCAGATCCTACATACAAATCAT-3′ (nt 3103–3125).
PCR conditions and amplicon purificatio are described else-
where [8, 18].
AS-PCR was performed using the purifie PCR products and
the primers IN K65 5′-TCCAGTATTTGCCATAAAGIA-3′ (nt
2723–2743) or IN K65R 5′-CCAGTATTTGCCATAAAGIG-3′
(nt 2724–2743) and pol 3002 rc 5′-CTGTGGAAGCACATTGT-
ACTG-3′ (nt 2812–2835) for the K65R AS-PCR, IN Y181 5′-
CATACAAATCATCCATGTATTGIT-3′ (nt 3091–3114) or IN
Y181C 5′-ATACAAATCATCCATGTATTGIC-3′ (nt 3091–3115)
and pol 2981 5′-TCAGTACAATGTGCTTCCACAGG-3′ (nt
2981–3003) for the Y181C AS-PCR, and IN M184wt 5′-AGAT-
CCTACATACAAATCATIC-3′ (nt 3101–3122) or IN M184I 5′-
CAGATCCTACATACAAATCATIT-3′ (nt 3101–3123) and pol
2981 for the M184I AS-PCR. Further details about the PCRs
and data analysis are described elsewhere [8, 18]. Each AS-PCR
assay has a detection limit of 10 HIV-1 DNA copies per reaction,
with a linear dynamic range of 16 logs. The estimated discrim-
inatory abilities of the different drug-susceptible and drug-re-
sistant sequences are as follows: 0.01% for detection of the
K103N mutation; 0.2% for detection of the Y181C, M184V,
and M184I mutations; and 0.4% for detection of the K65R
mutation as minority quasispecies. For each patient sample, an
individual cutoff was estimated on the basis of the viral load
as described elsewhere, because low viral loads diminish the
discriminatory ability of each assay [18]. Nonspecif c amplif -
cation by AS-PCR with use of SYBR green for detection of
double-stranded DNA was excluded by melting-curve analysis.
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